2021
DOI: 10.1007/s40472-021-00333-2
|View full text |Cite
|
Sign up to set email alerts
|

Tissue Engineering Strategies for Improving Beta Cell Transplantation Outcome

Abstract: Purpose of Review Beta cell replacement therapy as a form of islet transplantation is a promising alternative therapy with the possibility to make selected patients with type 1 diabetes (T1D) insulin independent. However, this technique faces challenges such as extensive activation of the host immune system post-transplantation, lifelong need for immunosuppression, and the scarcity of islet donor pancreas. Advancement in tissue engineering strategies can improve these challenges and allow for a m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
2
1

Relationship

2
4

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 170 publications
0
8
0
Order By: Relevance
“…Explanted mIslet+hASC scaffolds were positivelylabelled for islet and ASC markers, which confirm the presence of ASCs in the scaffolds together with islets throughout the in vivo studies. Five-times Intravenous administration of 5×10 6 ASCs to diabetic mouse models has been shown less efficient since ASCs have been detected in lungs, spleen and peritubular regions but not in the pancreas post infusion [68]. However, our data shows the presence of ASCs in scaffolds 60 days post implantation and this can support the beneficial effects of ASCs on preserving the islet function.…”
Section: Discussionmentioning
confidence: 46%
See 3 more Smart Citations
“…Explanted mIslet+hASC scaffolds were positivelylabelled for islet and ASC markers, which confirm the presence of ASCs in the scaffolds together with islets throughout the in vivo studies. Five-times Intravenous administration of 5×10 6 ASCs to diabetic mouse models has been shown less efficient since ASCs have been detected in lungs, spleen and peritubular regions but not in the pancreas post infusion [68]. However, our data shows the presence of ASCs in scaffolds 60 days post implantation and this can support the beneficial effects of ASCs on preserving the islet function.…”
Section: Discussionmentioning
confidence: 46%
“…In order to test this strategy and due to the lack of readily available human islets for this study, we fabricated 3D bioprinted scaffolds with 100 mouse islets and 1.2×10 6 human ASCs. The implantation of mIslet+hASC scaffolds to the IP site of diabetic mice could normalize blood glucose 7 days after implantation and this is almost similar to implanting full mass of mouse islets per graft (250 islets) under kidney capsule of diabetic mice.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…[5][6][7] Delivery of islets in hydrogelbased scaffolds have been explored over the years in several diabetic in vivo models and reported to have partial islet function and protection from immune rejection. [8] However, using large scaffolds comes with a price of limited oxygen, nutrients and insulin transports to and from the encapsulated islets, which subsequently lead to decreased islet survival and function. [9][10][11][12] Three-dimensional (3D) bioprinting could provide the advantages of a macroscopic delivery approach by retaining multiple islets in one potentially flat scaffold.…”
Section: Introductionmentioning
confidence: 99%